Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.63 |
| ▸ | PPARA | Q07869 | 15/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | PPARD | Q03181 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283015 | 1.00 | PPARG (0.63) | PPARGPPARACYP2C9CYP3A4KCNH2 | |
| SCHEMBL6531845 | 0.92 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL10367689 | 0.92 | PPARG (0.60) | PPARGPPARACYP2C9CYP3A4KCNH2 | |
| SCHEMBL6960213 | 0.91 | PPARG (0.59) | PPARGPPARAPPARD | |
| SCHEMBL6960061 | 0.90 | PPARG (0.57) | PPARGPPARAPPARD | |
| SCHEMBL10365768 | 0.90 | FFAR1 (0.54) | PPARGPPARACYP3A4 | |
| SCHEMBL6052105 | 0.89 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL6968221 | 0.89 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL9721218 | 0.88 | PPARG (0.55) | PPARGPPARA | |
| SCHEMBL6958644 | 0.87 | PPARG (0.50) | PPARGPPARACYP2C9CYP3A4PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682125-B2 | Compositions and methods for treating cognitive deficits | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-06-20 | — | — | US | claimed |
| US-9421197-B2 | Methods of generating hyper INOS expressing cells and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-08-23 | — | — | US | claimed |
| US-20140364461-A1 | METHOD OF TREATING DERMATOLOGICAL DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2014-12-11 | — | — | US | claimed |
| US-20140335105-A1 | METHODS OF GENERATING HYPER INOS EXPRESSING CELLS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-13 | — | — | US | claimed |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2014-08-21 | — | — | US | claimed |
| EP-2766018-A2 | RXR AGONISTS COMPOUNDS AND METHODS | Case Western Reserve University (US) | 2014-08-20 | — | — | EP | claimed |
| US-8796282-B2 | Method of treating dermatological disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-08-05 | — | — | US | claimed |
| US-8790925-B2 | Methods of generating hyper iNOS expressing cells and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-29 | — | — | US | claimed |
| US-20140170165-A1 | METHODS OF GENERATING HYPER INOS EXPRESSING CELLS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-06-19 | — | — | US | claimed |
| EP-1942898-B2 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2014-05-14 | — | — | EP | claimed |
| US-20090118337-A1 | Methods and compositions for treating inflammation | CASE WESTERN RESERVE UNIVERSITY | 2009-05-07 | — | — | US | claimed |
| US-20090042909-A1 | METHOD OF TREATING DERMATOLOGICAL DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2009-02-12 | — | — | US | claimed |
| WO-2008070230-A2 | METHODS AND COMPOSITIONS FOR TREATING CENTRAL NERVOS SYSTEM TUMORS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-06-12 | — | — | WO | claimed |
| WO-2008024749-A2 | METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC STROKE | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-02-28 | — | — | WO | claimed |
| WO-2006132928-A2 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2006-12-14 | — | — | WO | claimed |
| WO-2006034435-A2 | METHODS AND COMPOSITIONS FOR TREATING GLUCOSE-ASSOCIATED CONDITIONS, METABOLIC SYNDROME, DYSLIPIDEMIAS AND OTHER CONDITIONS | POINT THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-6579893-B1 | Related thiazolidinediones | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-06-17 | — | — | US | claimed |
| EP-0177353-B1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-04-11 | — | — | EP | claimed |
| US-4725610-A | TREATMENT OF HYPERLIPEMIA AND DIABETES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-02-16 | — | — | US | claimed |
| EP-0177353-A2 | Thiazolidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-04-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364461-A1 | METHOD OF TREATING DERMATOLOGICAL DISORDERS | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885CYP2C9 3105/4885 |
| US-20090042909-A1 | METHOD OF TREATING DERMATOLOGICAL DISORDERS | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885CYP2C9 3105/4885 |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | PPARG 20/4885PPARA 50/4885CYP2C9 2346/4885 |
| US-20090118337-A1 | Methods and compositions for treating inflammation | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885CYP2C9 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.